 |
 |
 |
 |
 |
Treatment Name: |
 |
Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) |
 |
 |
 |
 |
Phase: |
 |
Phase 3 |
 |
 |
 |
 |
 |
 |
Treatment ID#: |
 |
1924 |
 |
 |
 |
 |
Age Group: |
 |
Adults Only |
 |
 |
 |
 |
 |
 |
Min Karnofsky Score: |
 |
70: Cares for self, unable to perform normal activity or to do active work |
 |
 |
 |
 |
Conditions: |
 |
Prior Surgery is Allowed Prior Radiation is Sometimes Allowed Prior Chemotherapy is Sometimes Allowed IF you are interested in this trial, contact them as soon as possible, as there is a strict window of opportunity to join. Some of our members missed by a few days. |
 |
 |
 |
 |
 |
 |
Last Updated: |
 |
04/29/2012 |
 |
 |
 |
 |
Tumor Types: |
 |
Glioblastoma Multiforme |
 |
 |
 |
 |
 |
 |
 |
Comments: |
 |
See Novocure for more information on this device! |
 |
 |
 |
 |
 |
 |
Treatment Type: |
 |
Chemotherapy Less-Toxics |
 |
 |
 |
 |
Contact: |
 |
Gene Barnett MD : Professor and Director, Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center Cleveland Clinic Rose Ella Burkhardt Brain Tumor and Neuro-Oncology Center
Cleveland, OH 44195 USA Phone: 216-445-1379 Fax: 216-444-0924 E-mail: barnetg@ccf.org Website: my.clevelandclinic.org/brain_tumor/default.aspx |
 |
 |